Skip to main content
Clinical Trials/NCT03038958
NCT03038958
Completed
Phase 4

Comparison of Hyperbaric Prilocaine With Chloroprocaine for Intrathecal Anaesthesia in Day Case Knee Arthroscopy

Centre Hospitalier Universitaire Saint Pierre2 sites in 1 country80 target enrollmentApril 2016

Overview

Phase
Phase 4
Intervention
Isobaric 2-chloroprocaine
Conditions
Knee Arthroscopy
Sponsor
Centre Hospitalier Universitaire Saint Pierre
Enrollment
80
Locations
2
Primary Endpoint
Duration of sensory block
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

This study compares intrathecal 1% plain chloroprocaine with intrathecal 2% hyperbaric prilocaine for patients undergoing ambulatory knee arthroscopy in terms of efficacy and side effects

Registry
clinicaltrials.gov
Start Date
April 2016
End Date
July 2016
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Centre Hospitalier Universitaire Saint Pierre
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiology physical status (ASA) ≤ III
  • Age 18-80 year
  • Height between 160 and 185 cm
  • Signed informed consent obtained prior to any study specific assessments and procedures

Exclusion Criteria

  • Cardiac pathology (such as Heart failure, Aortic stenosis)
  • Coagulation disorders (INR\>1.3, platelet \< 80 000/mm3)
  • Known allergy to local anaesthetics
  • Disagreement of the patient

Arms & Interventions

Isobaric 2-chloroprocaine

The 50 mg dose of isobaric 2-chloroprocaine will be administered to patients undergoing ambulatory knee arthroscopy

Intervention: Isobaric 2-chloroprocaine

Hyperbaric prilocaine 2%

The dose of 50 mg of Hyperbaric prilocaine 2% will be administered to patients undergoing ambulatory knee arthroscopy

Intervention: Hyperbaric prilocaine

Outcomes

Primary Outcomes

Duration of sensory block

Time Frame: Until complete release of sensory block

Total duration of sensory block is the interval time between the end of intrathecal injection and the complete recovery of sensory block

Secondary Outcomes

  • Onset time of sensory block(up to 30 minutes)
  • Duration of motor block(Until complete regression of motor block)
  • Side-effects (hypotension, bradycardia, urinary retention)(up to 24 hours)
  • Pain assessed by Visual Analog Scale(up to 24 hours)
  • Onset time of motor block(up to 30 minutes)

Study Sites (2)

Loading locations...

Similar Trials